---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-25-005919"
form_type: "8-K"
ticker: "VNRX"
cik: "0000093314"
company_name: "VOLITIONRX LTD"
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:49:16.872822+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# VolitionRx Q2 2025 revenue ~$0.4M; net loss down 11% YoY; expects first human licensing deal

## Summary
- Q2 2025 revenue just over $0.4M; H1 2025 revenue up 15% YoY.
- Net loss decreased 11% in Q2 and 24% in H1 vs prior year; operating cash burn down 30% to $10.6M in H1.
- Cash & equivalents $2.3M at June 30, 2025; received $1.2M from direct offering post-quarter (director participation).
- Management expects first human diagnostics out-licensing deal in Q3 2025; confidential discussions with >10 companies.
- Conference call scheduled for August 15, 2025 at 8:30 a.m. ET.

## SEC filing metadata
- accession: 0001477932-25-005919
- form_type: 8-K
- ticker: VNRX
- cik: 0000093314
- company_name: VOLITIONRX LTD
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/93314/000147793225005919/0001477932-25-005919-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/93314/000147793225005919/vnrx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-25-005919
- JSON: https://secwatch.observer/filing/0001477932-25-005919.json
- Plain text: https://secwatch.observer/filing/0001477932-25-005919.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.